BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Genetown

  Seres Therapeutics Awarded Grant From CARB-X to Support Development of Microbiome Therapeutic Candidate

  The CARB-X grant provides Seres with up to $2.5 million of research funding with potential for an additional $3.1 million upon completion of milestones.

  November 7, 2017

   · 

  6 min read
• Business

  Acerus Reports Third Quarter 2017 Financial Results

  Product revenue for Q3 2017 grew to $1.6 million versus $1.4 million for Q3 2016 mainly due to increased sales of Natesto®.

  November 7, 2017

   · 

  10 min read
• Drug Development

  Alnylam Initiates ENVISION Phase III Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)

  It intends to file a New Drug Application (NDA) for givosiran at or around year-end 2018.

  November 7, 2017

   · 

  11 min read
• Business

  AVEO Reports Third Quarter 2017 Financial Results and Provides Business Update

  AVEO ended Q3 2017 with $37.4 million in cash, cash equivalents and marketable securities as compared with $23.3 million at December 31, 2016.

  November 7, 2017

   · 

  11 min read
• Genetown

  Optim Showcases ENTity Stroboscopy at Nation’s Largest Speech Pathology Conference

  Optim announced today the addition of the company’s ENTity Stroboscopy product to its MobileFEES System.

  November 7, 2017

   · 

  3 min read
• Drug Development

  Boehringer Ingelheim’s Efficacy and Safety Maintained in Patients Who Switched From Humira to Biosimilar Cyltezo

  The 48-week data showed that Cyltezo is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira in people with moderately-to-severely active RA, including in patients who switched from Humira to Cyltezo at week 24.

  November 7, 2017

   · 

  13 min read
• Lianluo Smart Announces Strategic Investment in Guardion Health Sciences

  Lianluo Smart today announced that the Company and related party Digital Grid together invested a total of $5M in GHS, a San Diego-based leader company focused on ocular health technologies and products.

  November 7, 2017

   · 

  3 min read
• Drug Development

  Amgen Announces New Analyses of High-Risk Patient Subgroups From Repatha (evolocumab) Cardiovascular Outcomes Study at AHA Scientific Sessions 2017

  Results will be presented at the AHA Scientific Sessions 2017 in Anaheim, Calif., Nov. 11-15.

  November 7, 2017

   · 

  21 min read
• Policy

  Statement from FDA Commissioner Scott Gottlieb, M.D., on implementation of agency’s streamlined development and review pathway for consumer tests that evaluate genetic health risks

  In its consideration of GHR tests, the FDA seeks to strike a balance that provides for an efficient pathway to bring these tests to consumers, without sacrificing the assurances offered by FDA oversight.

  November 7, 2017

   · 

  5 min read
• Business

  Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017

  Invitae today announced financial and operating results for the quarter ended September 30, 2017, including continued business momentum, double-digit sequential volume and revenue growth, and a strengthened financial position.

  November 7, 2017

   · 

  17 min read